This population-based cohort study assesses the association of testing in low-risk patients with subsequent care among low-risk primary care outpatients undergoing an annual health examination.
More
From Dr. Ronald Adler, why we should be wary of the promises of GRAIL and other liquid biopsy companies.
More
“My major piece of advice to anyone encountering preliminary studies is to be skeptical,” said journalism professor Sharon Dunwoody.
More
Now they are using lessons from the experience to urge action on the growing problem of drug-resistant infections before it’s too late.
More
COVID-19 could be an opportunity for the federal government to take a step back and decide whether quality programs should be significantly changed or permanently sunset, healthcare insiders said.
More
Last month, the CDC issued new guidelines warning that, given the low prevalence of the virus in the general population, even the most accurate tests could be wrong half of the time.
More
There's no evidence that a daily aspirin should be taken by most adults in good cardiovascular health, according to a new review. The risk of a major bleeding event due to the drug's blood thinning effects outweighs the benefit, the research said.
More
There are no clear lifesaving benefits to detecting past Covid-19 infections — and obvious risk of harm if the tests give misleading results.
More
Clinicians may avoid deprescribing a blood pressure medication because they fear that patients' blood pressure will rise dangerously. For those clinicians, the new OPTIMISE trial results may put their mind at ease.
More
Some communities considered community antibody testing as a way out of lockdown. But they’ve pulled back as they realized antibody testing is the Wild West in an oversight vacuum.
More
Producers looking to meet “unprecedented” demand were told they could sell tests as long as they validated them internally and filed for FDA emergency use authorization within 15 days. Shortly after came complaints of scams and unreliable tests.
More
Perspective from The New England Journal of Medicine — Covid-19 — A Reminder to Reason
More
Covid-19 makes it difficult to practice evidence-based medicine and just as hard to make decisions about the small questions that dictate day-to-day life.
More
H. Gilbert Welch and Vinay Prasad write that since the pandemic forced the medical care system to cancel elective surgeries and have fewer outpatient visits, Covid-19 provides a once in a lifetime opportunity to study if some, who are not acutely ill, do better with less medical care.
More
But an important caveat: exam quality matters
More
This Viewpoint discusses the importance of carefully evaluating SARS-CoV-2 vaccine candidates for safety and efficacy in the context of political pressure to accelerate the process, widespread vaccine hesitancy and refusal, and distrust of science.
More
As coronavirus health concerns, social isolation and job-loss stress take a toll, people turn to medications; “It can very quickly become a habit.”
More
Overall, AI’s implementation in everyday clinical care is less common than hype over the technology would suggest. Yet the coronavirus crisis has inspired some hospital systems to accelerate promising applications.
More
Some form of prospective payment is needed, experts say
More
Without the underlying data, promising vaccines and treatments are impossible to evaluate.
More